

Summary of DURB Recommendations

January 24, 2024

Meeting Date	Action Item	Status/DURB recommendation	Impact/Comments
October 2023	<p>Proposed addendum to biologic receptor modifiers (BRMs) protocol for plaque psoriasis</p> <p>Proposed protocol for Kanuma (sebelipase alfa)</p> <p>Proposed protocol for Vyjuvek (beremagene geperpavec)</p> <p>Proposed addendum to Duchenne muscular dystrophy products protocol</p>	<ul style="list-style-type: none"> <li>- The Board recommended the protocol</li> <li>- The Board recommended the protocol</li> <li>- The Board recommended the protocol with suggested changes to criterion #5</li> <li>- The Board recommended the protocol with suggested changes to criteria # 2, 6 and 10</li> </ul>	<p>The updated protocol will be shared with the Board at the next meeting</p> <p>The updated protocol will be shared with the Board at the next meeting</p>
July 2023	<p>Proposed protocol for Chimeric Antigen Receptor T-cell (CAR T-cell) products</p> <p>Proposed protocol for Qalsody (tofersen)</p> <p>Proposed addendum to the biologic receptor modifiers (BRMs) protocol for plaque psoriasis</p>	<ul style="list-style-type: none"> <li>- The Board recommended the protocol</li> <li>- The Board recommended the protocol</li> <li>- The Board tabled the protocol pending consult with a dermatologist</li> </ul>	
April 2023	<p>Proposed protocol for Skysona® (elivaldogene autotemcel)</p> <p>Proposed protocol for Zynteglo® (betibeglogene autotemcel)</p> <p>Proposed protocol for Hemgenix® (etranacogene dezaparvovec)</p> <p>Proposed protocol for Leqembi® (lecanemab-irmb)</p> <p>Proposed protocol for Livmarli® (maralixibat)</p>	<ul style="list-style-type: none"> <li>- The Board recommended the protocol</li> <li>- The Board recommended the protocol</li> <li>- The Board recommended the protocol</li> <li>- The Board recommended the protocol</li> <li>- The Board recommended the protocol with a suggestion to change criterion #5 to read: Medication is prescribed by or in consultation with a hepatologist, gastroenterologist, or other specialist with experience in the treatment of the disease</li> </ul>	<p>The updated information was presented at the next meeting</p>
January 2023	<p>Addendum to Spinraza®/Zolgensma® protocols</p> <p>Addendum to Imcivree® (setmelanotide) protocol</p> <p>Addendum to Dupixent® protocol (atopic dermatitis)</p>	<ul style="list-style-type: none"> <li>- The Board recommended the protocol</li> <li>- The Board recommended the protocol</li> <li>- The Board recommended the protocol</li> </ul>	

Summary of DURB Recommendations

Meeting Date	Action Item	Status/DURB recommendation	Impact/Comments
	Proposed protocol for Gattex® (teduglutide)	- The Board recommended the protocol with suggestion to remove the word “adult” in the background section.	The updated information was presented at the next meeting